Protalix is a publicly traded biotechnology company (NYSE Amex: PLX), that is producing recombinant therapeutic proteins through the ProCellEx™ plant cell system.
















Frequently Asked Questions:
  1. Where is Protalix Biotherapeutics headquartered?

    2. We are headquartered in Carmiel, Israel

  2. When was Protalix incorporated?

    3. Protalix was established in 1993.

  3. Where is Protalix BioTherapeutics registered?

    4. 2 Sunnit St. Science Park
    P.O. Box 455 Carmiel 21000 Israel
    Tel: 972-4-988-9488
    Fax: 972-4-988-9489

  4. How many employees does Protalix BioTherapeutics have?

    5. As of December 31, 2009, we had 182 employees, of whom 29 have an M.D. or a Ph.D. in their respective scientific fields

  5. Who are Protalix BioTherapeutics' independent registered auditors?

    6. Kesselman & Kesselman, Certified Public Accountant (Isr.),
    a member of PricewaterhouseCoopers International Limited,
    independent registered public accounting firm

    Trade Tower, 25 Hamered Street
    Tel Aviv 68125 Israel
    P.O. Box 452 Tel Aviv 61003 Israel
    Tel: 972-3-795-555
    Fax: 972-3-795-556

  6. When does Protalix BioTherapeutics' fiscal year end?

    7. December 31st

  7. How do I obtain information on Protalix?

    8. News releases, quarterly earnings, upcoming events, stock information and corporate governance can be accessed directly through this site.  The Annual Report on Form 10-K, proxy statements and other filings with the Securities and Exchange Commission can be accessed directly through this site or through the Securities and Exchange Commission at www.sec.gov.

  8. Who is Protalix's legal counsel?

    9. Morrison & Forrester is the legal team for Protalix and can be reached at 212-468-8000.

  9. Who can I contact for additional information on the Company?

    10. Investor inquiries can be directed to:

    or:

    Marcy Strickler/Tim Ryan
    The Trout Group LLC
    Tel (646) 378-2927
    Fax (646) 378-2901
    /

  10. Who is Protalix's transfer agent and how does a registered shareholder contact the agent regarding account information?

    11. American Stock Transfer
    59 Maiden Lane
    Plaza Level
    New York, NY 10038
    800-937-5449

  11. What exchange does Protalix's common stock trade on and what are its ticker symbol and pertinent identifier numbers?

    12. Protalix trades on the NYSE:Amex under the ticker symbol PLX.
    The Company's CUSIP is 74365A101
    The Company's U.S. ISIN is US74365A1016

  12. Who is Protalix's Designated Market Maker on the NYSE:Amex?

    13. Kellogg Capital Markets, LLC.

  13. How many ordinary shares does Protalix have outstanding?

    14. On February 15, 2010, approximately 80,745,296 shares of the Registrant’s common stock, par value $0.001 per share, were outstanding

  14. Does Protalix pay a dividend?

    15. No, Protalix does not pay a dividend.

  15. When does Protalix release earnings?

    16. A specific date is set each quarter and announced in a press release, otherwise such results are reported on the relevant Q or K.

  16. When is Protalix's Annual Shareholders' Meeting?

    17. Protalix held its recent annual meeting in November 9, 2009. Once scheduled, the company will disclose the date and location of its next annual meeting in a press release.

  17. When was Protalix's initial public offering?

    18. The company became public through a reverse merger with Orthodontix Inc. This merger was completed on December 31, 2006. On October 25, 2007, the company issued and sold 10,000,000 shares of our common stock in an underwritten public offering at a price of $5.00 per share.

© 2007 Protalix Biotherapeutics. All Rights Reserved.